During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.
News|Articles|August 1, 2009
Formulary Digital Edition August 2009
Emerging risk factors and risk markers for CV disease; Focus on rivaroxaban; Drug Watch: Agents in late-stage development for the treatment of osteoarthritis and acute/chronic pain
Advertisement
Advertisement
Related to this article
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Long-acting lenacapavir plus cabotegravir kept all 46 patients with HIV virally suppressed in recent trial
2
Chad Hatfield, Pharm.D., on the 340B uncertainty facing health systems| HSES 2026
3
Why biosimilars keep losing ground to brand-name rivals: A Q&A with Christine Johnston, MBA
4
On the relentless rise in healthcare spending, price vs. utilization, and what employers should do about it | A conversation with Katie Martin, M.P.A.
5